X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
The licensed technology possesses proprietary technology and intellectual property rights for the development of pharmaceutical drug formulations that are liposomal and/or emulsion-based formulations and that may incorporate Anti-Nuclear Antibodies (ANA).
Lead Product(s): Dactinomycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oncology Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding March 31, 2021
Details:
Actinomycin-D from Rasna Therapeutics will expand Tiziana Life Sciences's pipeline. The drug is on the WHO's List of Essential Medicines as the most effective medicines needed in a health system.
Lead Product(s): Dactinomycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Tiziana Life Sciences
Deal Size: $0.6 million Upfront Cash: $0.1 million
Deal Type: Acquisition April 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
